多功能智能水凝用于时空药物输送,用于协调糖尿病骨再生
Guang Shi1, Zhiqiang Yang1, Shenghui Lan2
1Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Bioactive materials
|November 11, 2025
概括
这项研究介绍了一种智能水凝,释放甲福明和PTHrP-1以对抗高血糖引起的骨老化,通过增强骨质生成和血管生成促进糖尿病骨修复.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 糖尿病并发症 糖尿病并发症
背景情况:
- 高血糖会加速骨衰老,阻碍糖尿病患者的骨再生.
- 氧化应激和细胞衰老是糖尿病骨缺陷的关键挑战.
研究的目的:
- 开发一种智能水凝,用于控制释放甲胺和PTHrP-1.
- 为了改善骨质的微环境和修复糖尿病的骨缺陷.
主要方法:
- 交叉连接氨酸 (HA) 与3-氨基乙酸 (PBA) 和聚乙醇 (PVA).
- 将甲胺 (Met) 纳入并将PTHrP-1定在聚多巴胺混合的纳米尺寸的烯酸伊米达酸框架-8 (P1@PZIF-8) 上.
- 在体外和体内评估动态,时空药物释放,细胞衰老,骨质生成和血管生成.
主要成果:
- 水凝表现出增强的机械强度和对Met,PTHrP-1和Zn2+的控制释放.
- 减少活性氧物种 (ROS),防止骨髓中酶干细胞 (BMSCs) 衰老,并促进骨质生成.
- 通过PI3K-AKT-mTOR抑制BMSCs衰老,并通过Wnt/β-catenin通路促进骨质生成.
- 增强血管新生,骨质新生和组织重塑 in vivo,减少糖尿病骨缺陷中的细胞衰老.
结论:
- 开发的水凝通过控制药物释放,有效地修复糖尿病骨缺陷.
- 这个平台加速了糖尿病环境中的骨再生和功能恢复.
- 智能水凝为糖尿病骨并发症提供了强有力的治疗策略.
相关概念视频
Secondary Active Transport
122.9K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
122.9K
Secondary Active Transport
12.8K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
12.8K
Modified-Release Drug Delivery Systems: Stimuli-Activated
177
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
177
Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
Oral Drug Delivery Systems: Continuous-Release Systems
308
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
308


